anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies .
Continuous breastfeeding support will be provided for the first 6 months through WhatsApp messaging application. Mothers will be contacted once a week through WhatsApp and feedback will be received on the breastfeeding process. The questions of the mother regarding breastfeeding will be answered by text / voice message or video call.
The experimental arm will last 7 consecutive nights and days. Participants will be asked to follow normal activity and sleep patterns, but they will wear an external nasal dilator strip during sleep. Immediately after waking the participants will measure their blood pressure and heart rate variability and complete a sleep diary to characterize subjective sleep quality. A wrist-based activity monitor will measure objective sleep quality during the experimental arm.
Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
<P>PROBLEM TO BE SOLVED: To efficiently manufacture a solid bath salt by preventing a solid bath salt composition from sticking to the surface of a roll of a briquette machine for the manufacture of the solid bath salt.  <P>SOLUTION: Solid bath salt is manufactured by supplying a solid bath salt composition to a briquette machine for the manufacture of the solid bath salt. The briquette machine for the manufacture of the solid bath salt is equipped with a pair of rolls 1 rotationally driven in synchronization with each other. Each of the rolls 1 has a pocket 2 on the circumferential surface. The roll 1 is constituted of a roll body 3 and a thermal-sprayed cermet layer 4 formed on the circumferential surface of the roll body 3 including the inside surface of the pocket 2. Cermet contains tungsten carbide (WC) and has a high hardness. The Rockwell hardness of the thermal-spray layer 4 is not lower than 60.  <P>COPYRIGHT: (C)2007,JPO&INPIT
There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dose of AVINZA. It is better to underestimate a patient’s 24-hour oral morphine dose and make available rescue medication than to overestimate the 24-hour oral morphine dose and manage an adverse experience or overdose. The following general points should be considered regarding opioid conversions.

Parenteral to oral morphine ratio: Anywhere from 3 to 6 mg of oral morphine may be required to provide pain relief equivalent to 1 mg of parenteral morphine. Based on this rationale, a reasonable starting dose of AVINZA would be approximately three times the previous daily parenteral morphine requirement.

Other parenteral or oral non-morphine opioids to oral morphine sulfate: Physicians and other healthcare professionals are advised to refer to published relative potency information, keeping in mind that conversion ratios are only approximate. In general, it is safest to administer half of the estimated daily morphine requirement as the initial AVINZA dose once per day and then manage insufficient pain relief by supplementation with immediate-release morphine or other short-acting analgesics. (see Individualization of Dosage)
The efficacy and treatment outcome of a CML patient are heavily dependent on BCR::ABL1 kinase domain (KD) mutation status. Next-generation sequencing technology is a bright alternative to the previously used sanger sequencing method due to its global presence in diagnostic setups, massive parallel sequencing ability, and far better sensitivity. In the present study, we have demonstrated a new protocol for kinase domain mutation analysis using the next-generation sequencing (NGS) method using the ion torrent sequencing platform. This protocol uses RNA as the starting material, followed by nested PCR to amplify the fusion transcript, which is subsequently used as a template for NGS. Initial validation and comparison of this assay with the sanger sequencing (SS) method yielded 95.23% agreement. CML samples (n = 121) with a failure to TKI response were subjected to this newly developed NGS-based assay to detect KD mutations, from which samples were found to have mutations with a sensitivity ranging from 2.32 to 93.41%. A total of 34.71% of samples (n = 42) were found to be positive for one or more KD mutations, whereas 65.29% of samples (n = 81) were found to be negative. Nine samples out of 42 positive samples, i.e., 21.42%, were found to have compound mutations. This is one of the first studies from India, which includes more than 160 samples and is analyzed by the NGS approach for KD mutation analysis.
Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To perform imaging very simply by reconstructing the image of the object with a small-sized detector. SOLUTION: The scanning trajectory about the object 12 includes a first scanning circle, a second scanning circle, and a helical scanning path connecting the first scanning circle and the second scanning circle. The scanning trajectory is then sampled with positions of cone beam source 10. Cone beam energy is emitted along the scanning trajectory from each of the positions of cone beam source 10 towards a portion of the object. Cone beam energy passing through the object is acquired on a detector as cone beam projection data. The cone beam projection data is then masked with a plurality of masks. Each of the masks remove cone beam projection data that is outside the region of interest of the object and retain cone beam projection data that is within the region of interest of the object. An image of the region of interest of the object is reconstructed from the masked cone beam projection data.
The efficacy of Campral in the maintenance of abstinence was supported by three clinical studies involving a total of 998 patients who were administered at least one dose of Campral or placebo as an adjunct to psychosocial therapy. Each study was a double-blind, placebo-controlled trial in alcohol-dependent patients who had undergone inpatient detoxification and were abstinent from alcohol on the day of randomization. Study durations ranged from 90 days to 360 days. Campral proved superior to placebo in maintaining abstinence, as indicated by a greater percentage of subjects being assessed as continuously abstinent throughout treatment.

In a fourth study, the efficacy of Campral was evaluated in alcoholics, including patients with a history of polysubstance abuse and patients who had not undergone detoxification and were not required to be abstinent at baseline. This study failed to demonstrate superiority of Campral over placebo.
PURPOSE: To assess the feasibility of using multifunction instruments to measure axial length for monitoring myopia progression in children and adults.
METHODS: Axial length was measured in 60 children (aged 6-18 years) and 60 adults (aged 19-50 years) with multifunction instruments (Myah and Myopia Master) and stand-alone biometers (Lenstar LS900 and IOLMaster 700). Repeatability (measurements by the same examiner) and reproducibility (measurements by different examiners) were computed as the within-subject standard deviation (Sw) and 95% limits of agreement (LoA). Inter-instrument agreement was computed as intraclass correlation coefficients. The threshold for detecting myopic progression was taken as 0.1 mm. Measures were repeated only in children following the administration of 1% tropicamide to determine the impact of cycloplegia on axial length.
RESULTS: Overall, the IOLMaster 700 had the best repeatability in children (0.014 mm) and adults (0.009 mm). Repeatability Sw values for all devices ranged from 0.005 to 0.021 mm (children) and 0.003 to 0.016 mm (adults). In children, reproducibility fell within 0.1 mm 95% of the time for the Myah, Myopia Master and IOLMaster 700. Agreement among all devices was classified as excellent (ICC 0.999; 95% CI 0.998-0.999), but the 95% LoA among the Myah, Myopia Master and Lenstar LS900 was ≥0.1 mm. Cycloplegia had no statistically significant effect on axial length (all p > 0.13).
CONCLUSIONS: The Myah and Myopia Master multifunction instruments demonstrated good repeatability and reproducibility, and their accuracy was comparable to stand-alone biometers. Axial length measurements using different instruments can be considered interchangeable but should be compared with some caution. Accurate axial length measurements can be obtained without cycloplegia. The multifunction instruments Myah and Myopia Master are as well suited for monitoring myopia progression in children as the stand-alone biometers IOLMaster 700 and Lenstar LS900.
The invention provides a fusion protein KP-Ag1 used as a Klebsiella pneumoniae vaccine antigen, which consists of KP6 protein, KP21 protein and KP24 protein connected by flexible amino acid Linker; wherein the amino acid sequence of KP6 is SEQ ID NO. 4, the amino acid sequence of KP21 is SEQ ID NO. 5, and the amino acid sequence of KP24 is SEQ ID NO. 6. The invention also provides an expression vector and a recombinant engineering drawing thereof and application of the recombinant engineering drawing as Klebsiella pneumoniae antigen. The antigen protein prepared by the method can effectively stimulate organisms to generate higher humoral immune response, can provide obvious protection effect on killing dose of Klebsiella pneumoniae infection, and can be used as a candidate antigen of Klebsiella pneumoniae vaccine.
Provided are a transposase, a transposon, a transposon system and the use thereof. The transposase is a mutant transposase or a fusion transposase. Compared with a wild-type PS transposase represented as SEQ ID NO: 1, the mutant transposase contains amino acid mutation. The fusion transposase is formed by fusing a functional polypeptide onto the wild-type PS transposase or a mutant thereof. Compared with a wild-type PS transposon, the transposon of the present invention contains nucleotide mutation and/or TIR multi-copies in tandem and/or TA multi-copies in tandem. The transposon system contains the transposase or a polynucleotide encoding same, and the transposon or the PS transposon. A JL transposase, a JL transposon, and a JL transposon system containing said JL transposase and JL transposon, which are obtained by engineering transformation of the wild-type PS transposase by the means described above remarkably improve the transposition gene integration efficiency.
Investigators plan to conduct a prospective pilot phase II trial of GTX-SBRT as neoadjuvant treatment of borderline resectable pancreatic cancer. After informed consent, pretreatment pancreatic tumor tissues will be collected and immediately frozen at the time of staging endoscopic ultrasound (EUS). Ribonucleic acid (RNA) will be extracted from tumor specimens and run on microarray analysis to determine radiosensitivity index score. Borderline resectable (BR) patients will be treated with 3 cycles of GTX chemotherapy followed by SBRT. They will be restaged and evaluated for resectability 3 to 4 weeks later. Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery.
Osteoarthritis is a widespread chronic degenerative disease marked by the deterioration of articular cartilage, modifications in subchondral bone, and a spectrum of symptoms, including pain, stiffness, and disability. Ultimately, this condition impairs the patient's quality of life. This study aimed to evaluate the therapeutic efficacy of standardized Boswellia serrata gum resin extract (BSRE) in a rat model of monosodium iodoacetate (MIA)-induced osteoarthritis. A total of 60 rats were allocated into six groups: normal control group (NC), osteoarthritis control (injected with MIA, OC), O + B50 (injected with MIA and treated with 50 mg/kg body weight (BW) BSRE), O + B75 (injected with MIA and treated with 75 mg/kg BW BSRE), O + B100 (injected with MIA and treated with 100 mg/kg BW BSRE), and O + M (injected with MIA and treated with 150 mg/kg BW methyl sulfonyl methane). Several parameters, including knee joint swelling, histopathological changes, and the expression of collagen type II alpha 1 (COL2A1) and aggrecan, were comprehensively assessed. Concurrently, the serum levels and mRNA expression of inflammatory mediators, cytokines, and matrix metalloproteinases (MMPs) were analyzed in both the serum and knee joint synovium. The results demonstrated that BSRE significantly mitigated knee joint swelling, cartilage destruction, and tissue deformation. Notably, BSRE administration markedly upregulated the expression of COL2A1 and aggrecan while concurrently reducing levels of nitric oxide, prostaglandin E2, leukotriene B4, interleukin (IL)-6, and tumor necrosis factor (TNF)-α. Furthermore, a substantial decrease was observed in the mRNA expression of inducible nitric oxide synthase, cyclooxygenase-2, 5-lipoxygenase, IL-6, TNF-α and MMP-3 and -13, thereby indicating promising therapeutic implications for osteoarthritis. In conclusion, BSRE exhibited anti-inflammatory properties and inhibited cartilage matrix degradation in a rat model of MIA-induced osteoarthritis, with the O + B100 group showing significant reductions in swelling and notable improvements in joint cartilage damage. These findings illuminate the preventive and therapeutic potential of BSRE for osteoarthritis treatment, emphasizing the criticality of exhaustive evaluation of novel compounds.
A low-molecular endotoxin activity inhibitor which is a substance neutralizing the activity of LPS and inhibiting the LPS-induced adhesion of leukocytes to endothelial cells. It has high specificity for LPS and is lowly cytotoxic. It can be mass-produced in a high yield. It is applicable to clinical use. The endotoxin activity inhibitor is characterized by being either of a surfactin represented by the following general formula (1) and a derivative thereof. [Chemical formula 8] General formula (1) In the general formula (1), R1 represents any one selected among L-leucine, L-isoleucine, and L-valine and R2 represents C8-22 alkyl.
Following the baseline assessment, participants randomized to receive placebo pill will follow the same dosing schedule as the active arm. They will return to the lab on Day 9 (or Days 10, 11 if necessary) for testing and continue at that dosing schedule for eight additional days (Days 10-17) for mobile monitoring.
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for producing and culturing fibroblast-like cells from a newborn's umbilical cord. That is ensured by umbilical cord sampling in healthy females following the delivery of the cesarean section. Umbilical cord is washed three times with sterile Hanks solution with an antibiotic of blood clots and mucus. Blood vessels are removed. Remaining fabric is ground, material is transferred into centrifuge tubes and poured with 0.2 % collagenase solution. Tubes are placed in a temperature shaker at a temperature of +37 °C, rotation speed 100 rpm for 16 hours. Content is filtered into new test tubes. Sterile 0.02 % Versene solution is introduced into them at ratio of 1:1 and centrifuges are tested in a cold centrifuge for 20 minutes. Cell pellet is resuspended in complete nutrient medium and number of recovered viable cells is counted. Cells are inoculated into a culture flask. Culturing is carried out in COincubator and medium change every 5 days of cultivation. When cell monolayer confluence reaches 80 %, cells are re-crossed at ratio of 1:2.EFFECT: invention enables to obtain fibroblast-like cells without the risk of contaminated opportunistic flora.1 cl, 1 tbl
A system and method for examining a medical image. To accomplish the method, a digital image is accessed wherein the digital image is representative of the medical image. The digital image is analyzed using Computer Aided Detection (CAD) to detect candidate abnormalities. A CAD report is generated comprising at least one level of information associated with the detected candidate abnormalities. The CAD report is processed to produce a speech synthesized CAD report in accordance with the at least one level of information. The digital image is simultaneously displayed with the delivery of the speech synthesized CAD report whereby the user can examine the digital image while simultaneously listening to the CAD report.
Sufficient sleep is essential for individual well-being. Inadequate sleep has been shown to have significant negative impacts on our attention, cognition, and mood. The measurement of sleep from in-bed physiological signals has progressed to where commercial devices already incorporate this functionality. However, the prediction of sleep duration from previous awake activity is less studied. Previous studies have used daily exercise summaries, actigraph data, and pedometer data to predict sleep during individual nights. Building upon these, this article demonstrates how to predict a person's long-term average sleep length over the course of 30 days from Fitbit-recorded physical activity data alongside self-report surveys. Recursive Feature Elimination with Random Forest (RFE-RF) is used to extract the feature sets used by the machine learning models, and sex differences in the feature sets and performances of different machine learning models are then examined. The feature selection process demonstrates that previous sleep patterns and physical exercise are the most relevant kind of features for predicting sleep. Personality and depression metrics were also found to be relevant. When attempting to classify individuals as being long-term sleep-deprived, good performance was achieved across both the male, female, and combined data sets, with the highest-performing model achieving an AUC of 0.9762. The best-performing regression model for predicting the average nightly sleep time achieved an R-squared of 0.6861, with other models achieving similar results. When attempting to predict if a person who previously was obtaining sufficient sleep would become sleep-deprived, the best-performing model obtained an AUC of 0.9448.
Most adverse effects are mild and transient and occur early in the course of treatment. In controlled clinical trials of 3 to 4 months’ duration, discontinuation of labetalol hydrochloride due to one or more adverse effects was required in 7% of all patients. In these same trials, other agents with solely beta- blocking activity used in the control groups led to discontinuation in 8% to 10% of patients, and a centrally acting alpha-agonist led to discontinuation in 30% of patients.

The incidence rates of adverse reactions listed in the following table were derived from multicenter, controlled clinical trials comparing labetalol hydrochloride, placebo, metoprolol, and propranolol over treatment periods of 3 and 4 months. Where the frequency of adverse effects for labetalol hydrochloride and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by the investigator. If all reports are considered, the rates are somewhat higher (e.g., dizziness, 20%; nausea, 14%; fatigue, 11%), but the overall conclusions are unchanged.

The adverse effects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding patients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy.

Clinical trials also included studies utilizing daily doses up to 2400 mg in more severely hypertensive patients. Certain of the side effects increased with increasing dose, as shown in the following table that depicts the entire U.S. therapeutic trials data base for adverse reactions that are clearly or possibly dose related.

In addition, a number of other less common adverse events have been reported:
Chinese participants with HER2+ advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma, or colorectal cancer receive tucatinib 300 mg by mouth twice daily during 21-day cycles. Treatment continues until there is evidence of unacceptable toxicity or documented progression.
The present invention relates to liver medicinal powder which belongs to a traditional Chinese medicine product of a medicine of people's living class. The present invention is a Chinese medicine for curing hepatic diseases, the curative effect is enhanced, and the treatment cycle is shortened. The prescription comprises dendrobe, trumpetcreeper flower, corydalis tuber, bezoar, honeysuckle flower, schisandra, viola herb, etc. A fresh hen liver, a cony liver and a hen are used as extra conductant ingredients. The present invention has the preparing method that the hen is slaughtered, five viscera are removed, the medicines are pulverized, uniformly mixed, and are put in the hen together with the hen liver and the cony liver for steaming for 10 hours, and the traditional Chinese medicines are taken out and dried and made into powder. The power is divided into 15 parts, and people take one part every day. The optimal taking time is 22-0 o'clock at night, and 15 days is a course of treatment.
PURPOSE: To stably perform feeding and freezing of liq. medicine into recessed parts by providing a substantially similar thermal expansion coefficient to the first outer layer and the second outer layer in a multi-laminated blister film. CONSTITUTION: A blister film 12 includes a substantially moisture-impermeable intermediate layer 14. The pref. material for this intermediate layer 14 is aluminum with a thickness of 10-1,000 μm, pref. approximately 45 μm and it is sandwiched with the first outer layer 16 and the second outer layer 18, which are pref. prepd. of a polyamide, a polyvinyl chloride, a polypropylene or other polymer substances contg. such substances. In addition, the first outer layer and the second outer layer may be prepd. of the same or different materials and the thicknesses may be diffrent each other as far as they have substantially similar thermal expansion coefficients. E.g., the film consists of the first outer layer 16, the second outer layer 18 and an aluminum intermediate layer 14 positioned between them and the thickness of each layer is approximately 50 μm.